Justus Liebig University Giessen, Giessen, Germany
www.uni-giessen.de 

The natural product research group of Justus Liebig University Giessen (JLU) is developing a first-in-class antibiotic. The compounds are precision molecules selectively active against Gram-negative pathogenic bacteria. Based on a natural product, the optimized molecules inhibit the protein BamA, a so far unaddressed and highly promising antibiotic target specific for Gram-negative bacteria. There is a pressing need for new treatment option against multi drug-resistant (MDR) bacteria. JLU’s goal is to enable therapies in various indication like complicated urinary tract infections and lung infections including cystic fibrosis patients. 

Current Development Stage: Hit-to-Lead

CARB-X Investment: Initial investment of US$610k

Initial CARB-X Investment Date: January 16, 2025